Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bidirectional ePIPAC-OX plus systemic chemotherapy for unresectable colorectal peritoneal metastases
2019-002290-63Phase 2Active
- Sponsor
- Catharina Ziekenhuis
- Start
- Oct 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), sponsored by Catharina Ziekenhuis. Started Oct 2019; status: active.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-002290-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002290-63.